Gilead has racked up its second straight setback on simtuzumab, scrapping a mid-stage study for idiopathic pulmonary fibrosis after a data monitoring group concluded that the drug wasn"t working as expected. The drug, which blocks the LOXL2 enzyme, has … Read the full article on FierceBiotech »
Strike two: Gilead chalks up another setback for top pipeline prospect simtuzumab - FierceBiotech
No comments:
Post a Comment